FDA Grants Fast Track Designation to Kestrel's Oral Pan-KRAS Inhibitor KST-6051 for KRAS-Mutant Solid Tumors
核心洞察
The FDA has granted Fast Track designation to KST-6051 (搜索), an oral pan-KRAS (搜索) inhibitor, for advanced or metastatic solid tumors harboring KRAS mutations.
Kestrel Therapeutics (搜索) said the designation rests on its preclinical data package and will enable closer FDA collaboration during the ongoing Phase 1 FALCON trial.
FALCON (NCT07458347) is a first-in-human dose-escalation study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity, with first patient dosed April 28, 2026.
The U.S. Food and Drug Administration has granted Fast Track designation to KST-6051 (搜索), an oral pan-KRAS (搜索) inhibitor developed by Kestrel Therapeutics (搜索), for the treatment of patients with advanced or metastatic solid tumors harboring KRAS mutations. The designation, announced by the Watertown, Massachusetts-based clinical-stage biotechnology company, is based on the strength of the drug's preclinical data package, according to the developer.
Fast Track is intended to facilitate the development and expedite review of drugs that treat serious conditions and address an unmet medical need. Sponsors receiving the designation gain more frequent communication with the FDA throughout development and may be eligible for Accelerated Approval, Priority Review, and rolling review of a New Drug Application, provided relevant criteria are met.
"FDA Fast Track designation for KST-6051 (搜索) is an important regulatory milestone for Kestrel, based on the strength of our preclinical data package. This designation will allow us to work more closely with the FDA as we advance KST-6051 through our ongoing Phase 1 study, with the goal of bringing a much-needed treatment option to patients with KRAS (搜索)-mutant tumors as efficiently as possible," said Frank Haluska, MD, PhD, President and Chief Executive Officer of Kestrel Therapeutics (搜索).
FALCON Trial Design and Endpoints
KST-6051 (搜索) is being evaluated in the ongoing first-in-human, dose-escalation Phase 1 FALCON study (NCT07458347), which is enrolling patients with KRAS (搜索)-mutant advanced or metastatic solid tumors. The company announced that the first patient was dosed on April 28, 2026.
FALCON is assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KST-6051 (搜索) in patients with advanced or metastatic solid tumors harboring KRAS (搜索) mutations, including pancreatic ductal adenocarcinoma (搜索) (PDAC), colorectal cancer (搜索) (CRC), non-small cell lung cancer (搜索) (NSCLC), and other KRAS-driven malignancies.
Eligible patients are 18 years or older with histologically documented locally advanced or unresectable disease, documentation of a KRAS (搜索) mutation prior to the first treatment dose, and progression on or intolerance to standard treatments. Participants must also have an ECOG performance status of 0 or 1, adequate cardiovascular, hematological, liver, and renal function, and measurable disease per RECIST v1.1. Exclusion criteria include previous or current treatment with RAS or KRAS inhibitors, central nervous system tumors or metastases, and inability to swallow oral medications.
The primary endpoints are the number of patients with dose-limiting toxicities, treatment-emergent adverse events, or treatment-related adverse events. Secondary endpoints include half-life of KST-6051 (搜索), objective response rate, disease control rate, progression-free survival, and duration of stable disease. Patients are assigned to sequential cohorts with increasing doses of KST-6051, administered as an oral tablet, to determine the recommended dose for expansion. Treatment continues as long as patients benefit and can tolerate it. The dose-escalation phase will be followed by expansion cohorts in selected tumor types.
Mechanism and Preclinical Profile
KST-6051 (搜索) is described as a potential best-in-class, oral pan-KRAS (搜索) inhibitor designed as a potent and selective inhibitor of KRAS with activity against the protein in both its active (GTP-bound) and inactive (GDP-bound) states. In preclinical models, the agent demonstrated robust on-target pathway modulation, anti-proliferative activity, and efficacy at well-tolerated doses across multiple human KRAS-mutant tumor models. Kestrel's clinical development plans for KST-6051 are ultimately intended to address PDAC, CRC, NSCLC, and other KRAS-driven malignancies.
KRAS (搜索) is estimated to be mutated in approximately 30% of all malignancies, an area the company characterizes as one of significant unmet patient need.
Competitive Landscape and Corporate Agreements
KST-6051 (搜索) joins a growing field of agents targeting mutant KRAS (搜索) across solid tumor types. The FDA previously granted breakthrough therapy designation to olomorasib for previously treated, KRAS G12C-mutant advanced pancreatic cancer. In addition, preliminary data from the Phase 1/2 TARGET-D 101 trial (NCT07020221) demonstrated that VS-7375 elicited clinical activity across KRAS G12D-mutated pancreatic, colorectal, and lung cancers.
Kestrel Therapeutics (搜索) is a privately held clinical-stage biotechnology company focused on next-generation small-molecule inhibitors of mutated KRAS (搜索) proteins. The company is backed by life-science investors including Pfizer Ventures (搜索) and Santé Ventures (搜索), and has entered into a strategic agreement granting AbbVie an exclusive option to acquire the company based on defined development and regulatory milestones.